Rigel Pharmaceuticals | RIGL - أصول متداولة





أصول متداولة تغيير تاريخ
Agenus USD 95.28M 38.15M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Anika Therapeutics USD 93.56M 9.8M 2026-03
Arrowhead Research USD 1.84B 665.36M 2026-03
AstraZeneca USD 29.61B 890M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Celldex Therapeutics USD 459.22M 75.44M 2026-03
Daiichi Sankyo JPY 2.1T 218.5B 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Halozyme Therapeutics USD 1B 177.83M 2026-03
Heron Therapeutics USD 228.98M 9.08M 2026-03
Intrexon USD 23.72M 45.04M 2024-06
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
Ligand Pharmaceuticals USD 865.42M 33.14M 2026-03
MacroGenics USD 182.52M 37.42M 2026-03
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Pfizer USD 42.82B 76M 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
Veracyte USD 522.17M 33.8M 2026-03